Analysis of the trade name of Sotoracib (AMG 510) and naming differences in different countries

Sotorasib (original development code AMG 510) is an oral small molecule inhibitor that targets the KRAS G12C mutation and is used to treat non-small cell lung cancer (NSCLC) and other solid tumors harboring this specific mutation. This drug is on the market or has received accelerated approval in many countries and regions around the world. There are certain differences in its trade name and registered name. This is mainly related to the drug registration system and brand strategy of each country.

In the United States, the trade name of sotorasibu is Lumakras®, which is promoted and sold by AstraZeneca (AstraZeneca). Lumakras is the first KRAS G12C targeted inhibitor approved by the FDA for the treatment of advanced KRAS G12C mutated patients who have received standard treatments. NSCLC patients. This name is widely used in clinical literature and patient education materials to facilitate identification and communication between physicians and patients.

In Europe and elsewhere, sotorasiib is also registered under the name Lumykras® or a similar name. Although the core active ingredients are the same, the names may be slightly adjusted due to drug naming rules and trademark registration restrictions in various countries. For example, in Canada, Australia, and Japan, the official registered name is slightly different from the commercial name, but it is still usually labeled as Sotorasib in academic literature and prescriptions to facilitate unified drug identification and clinical study citation.

It is worth noting that sotorasib has not yet been officially launched in China, so there is no official trade name in the Chinese market. Patients and doctors should use Sotorasib or Lumakras/Lumykras as the common name when referring to foreign information. Understanding these nomenclature differences is important for international clinical trials, cross-border drug procurement, or literature reading to help avoid confusion about drug ingredients or misuse of drugs. Unified recognition of trade names and scientific names allows for more accurate efficacy evaluation, dose management and safety monitoring.

Reference link:https://www.drugs.com